セッション詳細
[O1]Oral Presentations 1
2025年3月17日(月) 13:50 〜 14:50
神戸国際会議場 メインホール(1F)
[O1-01]A tradeoff between enterovirus A71 particle stability and cell entry
*Ming Te Yeh1, Adam Catching2, Sara Capponi3, Simone Bianco4, Raul Andino2 (1. CAMaD, Osaka University (Japan), 2. University of California, San Francisco (United States of America), 3. IBM Almaden Research Center (United States of America), 4. Altos Labs (United States of America))
[O1-02]Evolution of SARS-CoV-2: 2024/25 winter update
*Kei Sato1 (1. The Institute of Medical Science, The University of Tokyo (Japan))
[O1-03]A strategy for virus survival: host adaptation of SARS-CoV-2
*Tokiko Watanabe1,2,3 (1. Research Institute for Microbial Diseases, Osaka University (Japan), 2. Center for Advanced Modalities and DDS (CAMaD), Osaka University (Japan), 3. Center for Infectious Disease Education and Research (CiDER), Osaka University (Japan))
[O1-04]Cryo-EM facility of Hokkaido University for vaccine development
*Katsumi Maenaka1, Hideo Fukuhara2, Shunsuke Kita1 (1. Faculty of Pharmaceutical Sciences, Hokkaido University (Japan), 2. International Institute for Zoonosis Control, Hokkaido University (Japan))
[O1-05]AI・データサイエンスを活用したワクチン研究
Vaccine research powered by AI and data science
*Eiryo Kawakami1,2,3 (1. Graduate School of Medicine, Chiba University (Japan), 2. Institute for Advanced Academic Research (IAAR), Chiba University (Japan), 3. Advanced Data Science Project, RIKEN Information R&D and Strategy Headquarters, RIKEN (Japan))
[O1-06]From Basic Research to Clinical Trials: Proposing a Comprehensive ELSI Framework for Vaccine Development in Japan
*Kaori Muto1 (1. Institute of Medical Science, The University of Tokyo (Japan))